Syndrome of rapid onset ESRD accounted for high hemodialysis catheter use—results of a 13-year Mayo Clinic incident hemodialysis study

Onuigbo, Macaulay; Agbasi, Nneoma

doi:10.3109/0886022x.2015.1088336

Cited by 6 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Onuigbo et al 24 investigated an incident hemodialysis cohort at Mayo Clinic, Rochester, between 2001 and 2013, and reported the newly described syndrome of rapid onset ESRD (SORO-ESRD) following acute kidney injury (AKI), which was related to subsequent cardiovascular mortality with high rates of dialysis catheter use. 25 In these studies, however, no information has been provided on patients with increasing eGFR and on the association of change in eGFR with different causes of death.…”

Section: Discussionmentioning

confidence: 99%

Association of Slopes of Estimated Glomerular Filtration Rate With Post–End-Stage Renal Disease Mortality in Patients With Advanced Chronic Kidney Disease Transitioning to Dialysis

Sumida

Molnár

Potukuchi

et al. 2016

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Objective To investigate the association of estimated glomerular filtration rate (eGFR) slopes prior to dialysis initiation with cause-specific mortality following dialysis initiation. Patients and Methods In this retrospective cohort study of 18,874 United States veterans who had transitioned to dialysis from October 1, 2007, through September 30, 2011, we examined the association of pre-end-stage renal disease (ESRD) eGFR slopes with all-cause, cardiovascular, and infection-related mortality during the post-ESRD period over a median follow-up of 2.0 years (interquartile range; 1.1–3.2 years). Associations were examined using Cox models with adjustment for potential confounders. Results Prior to transitioning to dialysis, 4,485 (23.8%), 5,633 (29.8%), and 7,942 (42.1%) patients experienced fast, moderate, and slow eGFR decline, respectively, and 814 (4.3%) had increasing eGFR (defined as eGFR slopes of <−10, −10 to <−5, −5 to <0, and ≥0 mL/min/1.73 m2/year). During the study period, a total of 9,744 all-cause, 2,702 cardiovascular, and 604 infection-related deaths were observed. Compared with patients with slow eGFR decline, those with moderate and fast eGFR decline had a higher risk of all-cause (adjusted hazard ratio [HR]: 1.06; 95% confidence interval [CI] 1.00–1.11 and HR: 1.11; 95%CI 1.04–1.18, respectively) and cardiovascular mortality (HR: 1.11; 95%CI 1.01–1.23 and HR: 1.13; 95%CI 1.00–1.27, respectively). In contrast, increasing eGFR was only associated with higher infection-related mortality (HR: 1.49; 95%CI 1.03–2.17). Conclusion Rapid eGFR decline is associated with higher all-cause and cardiovascular mortality, and increasing eGFR is associated with higher infection-related mortality among incident dialysis patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of Slopes of Estimated Glomerular Filtration Rate With Post–End-Stage Renal Disease Mortality in Patients With Advanced Chronic Kidney Disease Transitioning to Dialysis

Sumida

Molnár

Potukuchi

et al. 2016

Mayo Clinic Proceedings

View full text Add to dashboard Cite

show abstract

“…Rapid decline in kidney function to ESRD was considered to have occurred if a patient was documented to have estimated GFR >30 mL/min/1.73 m 2 within 3 months prior to the initiation of chronic dialysis . Incidentally, we must observe here that their definition very closely mirrored our standard definition of SORO‐ESRD . Lee et al revealed that 8 of 105 incident chronic dialysis patients in one dialysis unit (7.6%; 95% confidence interval [CI] 3.4%–14.5%) and 9 of 71 incident patients at another dialysis unit (12.7%, 95% CI 6.0%–22.7%), suffered rapid yet permanent decline in kidney function consistent with SORO‐ESRD …”

Section: Introductionmentioning

confidence: 84%

“…In November 2014, we conducted a retrospective analysis of individual patient‐level serum creatinine trajectories of all ESRD patients on maintenance hemodialysis for longer than 90 days at Mayo Clinic, Rochester, between January 1, 2001 and December 31, 2013. Details of the methodologies and logistics of this analysis have been previously described . The objective was to determine the incidence of SORO‐ESRD in our 13‐year ESRD hemodialysis cohort and to further analyze the impact of this syndrome specifically as it relates to renal transplant recipients (RTRs).…”

Section: Methodsmentioning

confidence: 99%

“…In 2010, we first described the syndrome of rapid onset end‐stage renal disease (SORO‐ESRD), from the Renal Unit of Mayo Clinic Health System, Eau Claire, in Northwestern Wisconsin, USA, in the journal, Renal Failure . This syndrome represents acute precipitate yet irreversible renal failure following acute kidney injury (AKI) in contradistinction to “classic” end‐stage renal disease (ESRD) where CKD to ESRD progression is progressive, linear, time‐dependent, and predictable over years to sometimes decades, going through penultimate CKD stages to inexorably end in ESRD, requiring permanent renal replacement therapy in the form of dialysis and/or renal transplantation . Remarkably, “classic” ESRD is typified by patients with CKD who demonstrate often predictably increasing serum creatinine levels and, therefore, simultaneously falling estimated GFR levels, associated increasing proteinuria where applicable and ultimately leading inexorably to terminal symptomatic ESRD and the need for permanent renal replacement therapy (RRT) …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Mayo Clinic 13‐year investigation of the syndrome of rapid onset ESRD among renal transplant recipients: An analysis of the implications of renal allograft biopsy results

Onuigbo

Agbasi

2017

Hemodialysis International

Self Cite

View full text Add to dashboard Cite

Introduction: We first described the syndrome of rapid onset end stage renal disease (SORO-ESRD), acute yet irreversible renal failure, in 2010.Objective: The impact of SORO-ESRD renal allograft survival remains speculative and we plan to study this question.Methods: A retrospective analysis of individual adult patient-level serum creatinine trajectories of ESRD patients on maintenance hemodialysis for >90 days at Mayo Clinic, Rochester, 2001Rochester, -2013 Results: Of 1461 ESRD patients, 149 (10%) patients including 13 renal transplant recipients (RTRs) satisfied the diagnosis of SORO-ESRD -4 males, 9 females, 12 Caucasians/one other, age 45 (18-83) years. Serum creatinine was 1.4 (0.8-1.7) mg/dL in the last year before hemodialysis initiation. Initial hemodialysis access was a dialysis catheter in all 13 patients. AKI precipitating SORO-ESRD followed acute rejection (4), postoperative (2), tubulo-interstitial nephritis (2), unknown (2), infection/sepsis (1), contrast nephropathy (1), BKV nephropathy (1), and cardio-renal syndrome (1). Renal allograft survival was 1469 (277-4939) days (4 years). Renal allograft biopsies were available in 9/14 (69%) RTRs -Four showed acute rejection, two of which followed interruption of immunosuppression, three revealed acute tubular necrosis and four others also showed chronic transplant glomerulopathy. Time on hemodialysis was 856 (129-1630) days (2.4 years). 5/13 RTRs with SORO-ESRD (38%) died -3 (60%) following cardiac arrest, 2 (40%) after stopping hemodialysis. 4/13 (31%) were re-transplanted in the period of this study.Conclusion: SORO-ESRD contributed significantly to late renal allograft loss and return to hemodialysis with 100% initial dialysis catheter rate. Potentially preventable causes of AKI leading to SORO-ESRD were identified. The application of experience gained from such studies would help reduce late renal allograft loss and the need for re-transplantation. This would further help reduce Correspondence to: M. A. Onuigbo,

show abstract

“…A just published report from Saudi Arabia revealed an association of continued angiotensin blockade with hospital-acquired AKI (15). Besides, we had demonstrated in a 13-year retrospective analysis of 1461 ESRD patient managed at Mayo Clinic, Rochester, 2001-2013, an incidence rate of SORO-ESRD of 10% but we were not able to show any association between SORO-ESRD and concurrent angiotensin blockade (21). Finally, we would call for caution in the use of angiotensin blockade in older (>65-year old) patients with advanced CKD.…”

Section: Lorffab and Soro-esrdmentioning

confidence: 96%

Late onset renal failure from angiotensin blockade (LORFFAB) and the syndrome of rapid onset endstage renal disease (SORO-ESRD) revisited – Two case reports from Mayo Clinic Health System, Northwestern Wisconsin, USA; a review paper

Onuigbo¹,

Samuel²,

Agbasi³

2018

J Renal Inj Prev

Self Cite

View full text Add to dashboard Cite

In 2005, we had described for the first time, the syndrome of late onset renal failure from angiotensin blockade (LORFFAB), represented by the observed accelerated loss of kidney function in patients on a priori stable doses of an angiotensin converting enzyme inhibitor and/or an angiotensin receptor blocker, for more than three months, with this acute kidney injury (AKI) occurring despite the absence of any identifiable known precipitating factors. Moreover, in 2010, we had described the syndrome of rapid onset end-stage renal disease (SORO-ESRD), represented by acute yet irreversible renal failure following medical illness or surgical procedures, again sometimes in association with concurrent angiotensin blockade. In this article, we describe two representative case reports, one each of both syndromes, and discuss the implications of LORFFAB and SORO-ESRD in current nephrology practice paradigms.Please cite this paper as: Onuigbo M, Samuel E, Agbasi N. Late onset renal failure from angiotensin blockade (LORFFAB) and the syndrome of rapid onset end-stage renal disease (SORO-ESRD) revisited -Two case reports from Mayo Clinic Health System, Northwestern Wisconsin, USA; a review paper. J Renal Inj Prev. 2018;7(2):58-63. DOI: 10.15171/jrip.2018.15. In 2005, we described for the first time, the syndrome of late onset renal failure from angiotensin blockade (LORFFAB). This is accelerated loss of kidney function in patients on a priori stable doses of an angiotensin converting enzyme inhibitor and/or an angiotensin receptor blocker (ARB), for more than 3 months, with this acute kidney injury (AKI) occurring in the absence of any identifiable known precipitating factors. Moreover, in 2010, we described the syndrome of rapid onset end-stage renal disease (SORO-ESRD). This is acute yet irreversible renal failure following medical illness or surgical procedures, again sometimes in association with concurrent angiotensin blockade. In this article, we describe two representative case reports, one case for LORFFAB and another case for SORO-ESRD and subsequently discuss the implications of LORFFAB and SORO-ESRD in current nephrology practice paradigms. Whereas we support the consensus that angiotensin blockade, for now, remains the mainstay of renoprotection, we however must draw attention to the potential for nephrotoxicity from angiotensin blockade under certain clinical scenarios including the ones described here and more. The association of LORFFAB and SORO-ESRD demands further investigation.

show abstract

Syndrome of rapid onset ESRD accounted for high hemodialysis catheter use—results of a 13-year Mayo Clinic incident hemodialysis study

Cited by 6 publications

References 26 publications

Association of Slopes of Estimated Glomerular Filtration Rate With Post–End-Stage Renal Disease Mortality in Patients With Advanced Chronic Kidney Disease Transitioning to Dialysis

Association of Slopes of Estimated Glomerular Filtration Rate With Post–End-Stage Renal Disease Mortality in Patients With Advanced Chronic Kidney Disease Transitioning to Dialysis

A Mayo Clinic 13‐year investigation of the syndrome of rapid onset ESRD among renal transplant recipients: An analysis of the implications of renal allograft biopsy results

Late onset renal failure from angiotensin blockade (LORFFAB) and the syndrome of rapid onset endstage renal disease (SORO-ESRD) revisited – Two case reports from Mayo Clinic Health System, Northwestern Wisconsin, USA; a review paper

Contact Info

Product

Resources

About